Skip to main content
Fig. 4 | Clinical Epigenetics

Fig. 4

From: A miRNA screening identifies miR-192-5p as associated with response to azacitidine and lenalidomide therapy in myelodysplastic syndromes

Fig. 4

miR-192-5p directly targets BCL2 Promoter Sequence. THP-1 cells were transduced with miR-192-5p mimics, positive control, or empty vector (negative control) and a 3′-UTR BCL2 reporter vector. Results are expressed as the relative ratio of Firefly luciferase activity to Renilla luciferase activity using the negative control as reference. Data represent at least three biological replicates with three technical replicates and are shown as mean ± SD. *p < 0.05 versus negative control, by one-way ANOVA using Dunnett’s multiple comparisons in GraphPad Prism 5

Back to article page

Clinical Epigenetics

ISSN: 1868-7083

Contact us